Anaphylaxis
Risk of severe allergic reaction. Seek urgent medical help if serious symptoms occur.
Leaflet RYBREVANT 3520mg solution for injection
- Product code:
- W71842001
- Quantity:
- 1
- Indicated for:
- non-small cell lung cancer
- Route of administration:
- injectable
- Substance:
- amivantamab (monoclonal antibody)
- ATC
- L01FX18 — Antineoplastic and immunomodulating agents | Monoclonal antibodies and antibody drug conjugates | Other monoclonal antibodies and antibody drug conjugates
Precautions:
Additional monitoring
This medicine is subject to additional monitoring.
Breastfeeding warning
Use during breastfeeding only on medical advice.
Pregnancy warning
Use during pregnancy only on medical advice.
Amivantamab is a monoclonal antibody used in the treatment of non-small cell lung cancer (NSCLC) with mutations in the EGFR (epidermal growth factor receptor) gene. It works by binding to EGFR and MET receptors, thereby inhibiting cellular signaling that promotes cancer cell growth and survival.
Amivantamab is administered intravenously, typically once a week during the initial weeks of treatment, followed by less frequent administrations as per the protocol established by the physician. The treatment is particularly indicated for patients with EGFR exon 20 mutations, which are resistant to other targeted therapies.
Common side effects include infusion-related reactions, skin rashes, diarrhea, nausea, and fatigue. In rare cases, severe reactions such as pneumonitis or liver toxicity may occur.
Patients receiving amivantamab should be closely monitored for adverse reactions and treatment efficacy. It is essential that the treatment is administered under the supervision of an oncologist experienced in targeted therapies. Amivantamab represents a promising option for patients with advanced NSCLC, offering a chance to control the disease in cases with specific genetic mutations.
Amivantamab is administered intravenously, typically once a week during the initial weeks of treatment, followed by less frequent administrations as per the protocol established by the physician. The treatment is particularly indicated for patients with EGFR exon 20 mutations, which are resistant to other targeted therapies.
Common side effects include infusion-related reactions, skin rashes, diarrhea, nausea, and fatigue. In rare cases, severe reactions such as pneumonitis or liver toxicity may occur.
Patients receiving amivantamab should be closely monitored for adverse reactions and treatment efficacy. It is essential that the treatment is administered under the supervision of an oncologist experienced in targeted therapies. Amivantamab represents a promising option for patients with advanced NSCLC, offering a chance to control the disease in cases with specific genetic mutations.
Official documents
General data about RYBREVANT 3520mg
- Substance:
- amivantamab
- Date of latest medicines list:
- 01-05-2026
- Product code:
- W71842001
- Concentration:
- 3520mg
- Pharmaceutical form:
- solution for injection
- Quantity:
- 1
- Product type:
- Original
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for amivantamab
Concentrations available for amivantamab
- 1600mg
- 2240mg
- 2400mg
- 350mg
- 3520mg